Research News

PSA screening significantly cuts risk of death from prostate cancer, review finds

BMJ 2017; 358 doi: https://doi.org/10.1136/bmj.j4120 (Published 05 September 2017) Cite this as: BMJ 2017;358:j4120
  1. Susan Mayor
  1. London

Prostate specific antigen (PSA) screening is associated with a reduction in the risk of death from prostate cancer by as much as a third, a review of conflicting randomised trials has found.1

Screening for prostate cancer with PSA has been common since the late 1980s, but two trials published in 2009 found contradictory results regarding its efficacy in reducing prostate cancer deaths. The PLCO (Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial) in the US found low rates of prostate cancer death that did not differ significantly between men who were screened and those who were not, while the ERSPC (European Randomized …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe